Sabine Tejpar

Summary

Affiliation: Katholieke Universiteit Leuven
Country: Belgium

Publications

  1. ncbi request reprint Molecular and genetic defects in colorectal tumorigenesis
    Sabine Tejpar
    Center for Human Genetics, University Hospital Gasthuisberg, Leuven, Belgium
    Best Pract Res Clin Gastroenterol 16:171-85. 2002
  2. doi request reprint Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
    Wendy De Roock
    Centre for Human Genetics, KU Leuven, Leuven, Belgium
    Lancet Oncol 11:753-62. 2010
  3. doi request reprint Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
    Wendy De Roock
    Center for Human Genetics, University of Leuven, Leuven, Belgium
    JAMA 304:1812-20. 2010
  4. doi request reprint KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
    Wendy De Roock
    Centre for Human Genetics, Catholic University of Leuven, Leuven, Belgium
    Lancet Oncol 12:594-603. 2011
  5. doi request reprint Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status
    Eric Van Cutsem
    University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    J Clin Oncol 29:2011-9. 2011
  6. doi request reprint Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab
    Sabine Tejpar
    Digestive Oncology Unit, University Hospital Gasthuisberg, Herestraat 49, Leuven, Belgium B 3000
    J Clin Oncol 30:3570-7. 2012
  7. pmc Overcoming resistance to antiangiogenic therapies
    Sabine Tejpar
    Digestive Oncology Unit, University Hospital Gasthuisberg, Herestraat 49, Leuven B 3000, Belgium
    Oncologist 17:1039-50. 2012
  8. pmc Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients
    Raphael Marechal
    Department of Gastroenterology, GI Cancer Unit, Erasme University Hospital, Universite Libre de Bruxelles, Brussels, Belgium
    BMC Cancer 10:340. 2010
  9. ncbi request reprint Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study
    Sabine Tejpar
    Digestive Oncology Unit, Department of Internal Medicine, University Hospital Gasthuisberg, Leuven, Belgium
    Lancet Oncol 8:387-94. 2007
  10. pmc Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery
    Sabine Tejpar
    Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium
    Oncologist 15:390-404. 2010

Detail Information

Publications48

  1. ncbi request reprint Molecular and genetic defects in colorectal tumorigenesis
    Sabine Tejpar
    Center for Human Genetics, University Hospital Gasthuisberg, Leuven, Belgium
    Best Pract Res Clin Gastroenterol 16:171-85. 2002
    ..Further insight into colorectal tumorigenesis pathways can lead to the development of useful prognostic indicators and target preventive and therapeutic strategies in the management of colorectal cancer...
  2. doi request reprint Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
    Wendy De Roock
    Centre for Human Genetics, KU Leuven, Leuven, Belgium
    Lancet Oncol 11:753-62. 2010
    ....
  3. doi request reprint Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
    Wendy De Roock
    Center for Human Genetics, University of Leuven, Leuven, Belgium
    JAMA 304:1812-20. 2010
    ..Patients with metastatic colorectal cancer who have KRAS codon 12- or KRAS codon 13-mutated tumors are presently excluded from treatment with the anti-epidermal growth factor receptor monoclonal antibody cetuximab...
  4. doi request reprint KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
    Wendy De Roock
    Centre for Human Genetics, Catholic University of Leuven, Leuven, Belgium
    Lancet Oncol 12:594-603. 2011
    ..We review the role of mutations in genes other than KRAS on the efficacy of anti-EGFR therapy, and discuss strategies to target these oncogenic alterations alone or in combination with receptor tyrosine-kinase inhibition...
  5. doi request reprint Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status
    Eric Van Cutsem
    University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    J Clin Oncol 29:2011-9. 2011
    ..An updated survival analysis, including additional patients analyzed for tumor mutation status, was undertaken...
  6. doi request reprint Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab
    Sabine Tejpar
    Digestive Oncology Unit, University Hospital Gasthuisberg, Herestraat 49, Leuven, Belgium B 3000
    J Clin Oncol 30:3570-7. 2012
    ..We investigated in the first-line setting our previous finding that patients with chemorefractory KRAS G13D-mutated metastatic colorectal cancer (mCRC) benefit from cetuximab treatment...
  7. pmc Overcoming resistance to antiangiogenic therapies
    Sabine Tejpar
    Digestive Oncology Unit, University Hospital Gasthuisberg, Herestraat 49, Leuven B 3000, Belgium
    Oncologist 17:1039-50. 2012
    ..Integrating these concepts into the design and evaluation of new antiangiogenic therapies may help overcome resistance mechanisms and allow for greater efficacy over longer treatment periods...
  8. pmc Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients
    Raphael Marechal
    Department of Gastroenterology, GI Cancer Unit, Erasme University Hospital, Universite Libre de Bruxelles, Brussels, Belgium
    BMC Cancer 10:340. 2010
    ..Antibody-dependent cell-mediated cytotoxicity (ADCC) could be another possible mechanism of cetuximab antitumor effects and its specific contribution on the clinical activity of cetuximab is unknown...
  9. ncbi request reprint Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study
    Sabine Tejpar
    Digestive Oncology Unit, Department of Internal Medicine, University Hospital Gasthuisberg, Leuven, Belgium
    Lancet Oncol 8:387-94. 2007
    ..We aimed to assess the incidence, characteristics, and predictive factors of magnesium wasting during treatment with EGFR-targeting antibodies, and to study the pathophysiology of this phenomenon...
  10. pmc Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery
    Sabine Tejpar
    Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium
    Oncologist 15:390-404. 2010
    ....
  11. ncbi request reprint The multidisciplinary management of gastrointestinal cancer. The use of molecular markers in the diagnosis and treatment of colorectal cancer
    Sabine Tejpar
    Digestive Oncology Unit, Centre for Human Genetics, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    Best Pract Res Clin Gastroenterol 21:1071-87. 2007
    ..However, no molecular marker has yet made it into daily practice. In this review we will discuss some of the potential molecular markers, focus on the lessons learnt from marker development and identify strategies for the future...
  12. doi request reprint Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab
    Bart Jacobs
    Department of Pathology, Digestive Oncology Unit, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium
    J Clin Oncol 27:5068-74. 2009
    ....
  13. doi request reprint PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer
    Hans Prenen
    Department of Digestive Oncology, University Hospital Gasthuisberg, Leuven, Belgium
    Clin Cancer Res 15:3184-8. 2009
    ..Other mechanisms of resistance to EGFR inhibitors could involve activating mutations of the other main EGFR effector pathway, i.e., the PI3K/PTEN/AKT pathway...
  14. doi request reprint Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab
    Hubert Piessevaux
    Hubert Piessevaux, Cliniques Universitaires Saint Luc, Universite Catholique de Louvain, Brussels Marc Buyse, International Drug Development Institute, Louvain la Neuve Eric Van Cutsem and Sabine Tejpar, University Hospital Gasthuisberg, Leuven, Belgium Michael Schlichting and Steffen Heeger, Merck KGaA, Darmstadt and Carsten Bokemeyer, Universitatsklinikum Hamburg Eppendorf, Hamburg, Germany
    J Clin Oncol 31:3764-75. 2013
    ..This association was investigated in the first-line setting in the randomized CRYSTAL and OPUS mCRC trials, after controlling for KRAS tumor mutation status...
  15. ncbi request reprint Upregulation of Wilms' tumor gene 1 (WT1) in desmoid tumors
    Saeid Amini Nik
    Center for Human Genetics, University of Leuven, Leuven, Belgium
    Int J Cancer 114:202-8. 2005
    ..These results show that the wild-type WT1 gene is strongly overexpressed in beta-catenin mutant desmoid tumors and may play a role in tumorigenesis of desmoid tumors, similar to what has been suggested in some epithelial malignancies...
  16. doi request reprint Clinical biomarkers in oncology: focus on colorectal cancer
    Wendy De Roock
    Digestive Oncology Unit, Center for Human Genetics, University Hospital Gasthuisberg, Leuven, Belgium
    Mol Diagn Ther 13:103-14. 2009
    ..Further studies are needed to help integrate the latest findings into clinically useful tools for personalized medicine...
  17. ncbi request reprint Large deletions of the APC gene in 15% of mutation-negative patients with classical polyposis (FAP): a Belgian study
    Genevieve Michils
    Center for Human Genetics, University Hospital Leuven, Leuven, Belgium
    Hum Mutat 25:125-34. 2005
    ..In this article, we have included an overview of genomic rearrangements in the 5q21 region...
  18. doi request reprint Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer
    Eric Van Cutsem
    University Hospital Gasthuisberg, Digestive Oncology Unit, Herestraat 49, 3000 Leuven, Belgium
    N Engl J Med 360:1408-17. 2009
    ....
  19. doi request reprint Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours
    Eric Van Cutsem
    Digestive Oncology Unit, University Hospital Gasthuisberg, 3000 Leuven, Belgium
    Eur J Cancer 49:17-24. 2013
    ..To determine dose-limiting toxicities (DLTs), recommended phase II trial dose (RPTD), safety, preliminary antitumour activity and pharmacokinetics of intravenous aflibercept with irinotecan, 5-fluorouracil and leucovorin (LV5FU2)...
  20. doi request reprint VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
    Diether Lambrechts
    Laboratory of Translational Genetics, Vesalius Research Center, VIB and KULeuven, Leuven, Belgium
    Lancet Oncol 13:724-33. 2012
    ..We assessed whether genetic variants in the VEGF pathway could act as biomarkers for bevacizumab treatment outcome...
  21. ncbi request reprint TGF-beta modulates beta-Catenin stability and signaling in mesenchymal proliferations
    Saeid Amini Nik
    Department of Human Genetics, Catholic University of Leuven, Herestraat 49, Leuven, Belgium
    Exp Cell Res 313:2887-95. 2007
    ..This modulation of beta-Catenin levels by TGF-beta may be involved in determining the tumoral phenotype of the cells...
  22. doi request reprint Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study
    Eric Van Cutsem
    University Hospital Gasthuisberg, Leuven, Belgium
    J Clin Oncol 30:2861-8. 2012
    ..This article reports clinical and pharmacokinetic (PK) data...
  23. doi request reprint Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer
    Annelies Debucquoy
    Lab of Experimental Radiotherapy, Department of Radiation Oncology, CDG Building, Box 815, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    J Clin Oncol 27:2751-7. 2009
    ....
  24. doi request reprint EGFR-targeted therapy
    Loredana Vecchione
    Digestive Oncology Unit, University Hospital Gasthuisberg, Herestraat 49 bus 602 Be 3000, Leuven, Belgium
    Exp Cell Res 317:2765-71. 2011
    ....
  25. pmc External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds
    Ellen Bellon
    University of Leuven, Centre for Human Genetics, Research Unit Biomedical Quality Assurance Leuven, Herestraat 49, Box 602, 3000, Leuven, Belgium
    Oncologist 16:467-78. 2011
    ..We aim to further expand this program to more laboratories to provide a robust estimate of the quality of KRAS testing in Europe, and provide the basis for remedial measures and harmonization...
  26. pmc A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy
    Zenia Saridaki
    Laboratory of Tumor Cell Biology School of Medicine, University of Crete, Heraklion, Greece Laboratory of Molecular Digestive Oncology, Department of Oncology, Katholieke Universiteit Leuven, Leuven, Belgium
    Clin Cancer Res 20:4499-510. 2014
    ..We studied this biomarker's correlation to anti-EGFR monoclonal antibody (mAb) therapy response in patients with metastatic colorectal cancer...
  27. pmc Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer
    Ravit Geva
    Gastrointestinal Malignancies Service, Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel Department of Gastroenterology, Digestive Oncology Unit, University Hospitals Leuven, Leuven, Belgium
    Onco Targets Ther 6:53-8. 2013
    ..There is little data of the activity of bevacizumab in chemorefractory mCRC patients. The aim of this retrospective single center study was to evaluate the activity of bevacizumab combined with chemotherapy in this study population...
  28. doi request reprint Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study
    Nicola Personeni
    Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium
    Clin Cancer Res 14:5869-76. 2008
    ..The value of testing KRAS mutation status, in addition to EGFR GCN, was also explored...
  29. doi request reprint Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents
    Andreia Costa
    Digestive Oncology, University Hospital Gasthuisberg, Leuven, Belgium
    Target Oncol 6:227-33. 2011
    ..Using literature from peer-reviewed journals, this review reports the clinical trials findings and discusses the mechanisms and the treatment of hypomagnesaemia induced by anti-EGFR targeted agents...
  30. ncbi request reprint Oral capecitabine: bridging the Atlantic divide in colon cancer treatment
    Eric Van Cutsem
    University Hospital Gasthuisberg, Department of Internal Medicine, Herestraat 49, Leuven 3000, Bellgium
    Semin Oncol 32:43-51. 2005
    ..Capecitabine has also shown promising activity and good tolerability in combination with radiotherapy in rectal cancer...
  31. pmc Beta-catenin overexpression in Dupuytren's disease is unrelated to disease recurrence
    Ilse Degreef
    Orthopaedic Surgery Department, Hand Unit, University Hospitals Leuven, Pellenberg Campus, Weligerveld 1, 3212, Pellenberg, Belgium
    Clin Orthop Relat Res 467:838-45. 2009
    ..Clinical parameters for Dupuytren's diathesis remain the best way to predict recurrence risk...
  32. doi request reprint Immunohistochemical evidence for Zic1 coexpression with beta-catenin in the myofibroblast of Dupuytren disease
    Ilse Degreef
    Orthopaedic Department, Hand Unit, University Hospitals Leuven, Pellenberg, Belgium
    Scand J Plast Reconstr Surg Hand Surg 43:36-40. 2009
    ..The fibroblast in DD is an interesting model for future experiments...
  33. doi request reprint Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials
    Sabine Tejpar
    Molecular Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium
    JAMA Oncol . 2016
    ..Metastatic colorectal cancer (mCRC) is heterogeneous, and primary tumors arising from different regions of the colon are clinically and molecularly distinct...
  34. pmc Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching
    Linde De Smedt
    Translational Cell and Tissue Research Unit, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium
    Br J Cancer . 2016
    ..In the present study, we aimed to investigate the molecular signature of tumour budding cells and the corresponding tumour bulk...
  35. ncbi request reprint Pathogenic mutations and rare variants of the APC gene identified in 75 Belgian patients with familial adenomatous polyposis by fluorescent enzymatic mutation detection (EMD)
    Genevieve Michils
    Center for Human Genetics, University of Leuven, Leuven, Belgium
    Eur J Hum Genet 10:505-10. 2002
    ....
  36. doi request reprint Virtual chromoendoscopy (I-SCAN) detects more polyps in patients with Lynch syndrome: a randomized controlled crossover trial
    Raf Bisschops
    Department of Gastroenterology, University Hospital Leuven, Leuven, Belgium
    Endoscopy . 2017
    ..387 seconds; 95 %CI - 32.24 to 104.89). Conclusion Our data suggest that virtual chromoendoscopy with I-SCAN reduces the adenoma and polyp miss rate in patients with Lynch syndrome, independently of inspection time...
  37. ncbi request reprint Zic2 mutation causes holoprosencephaly via disruption of NODAL signalling
    Rob Houtmeyers
    Department of Oncology, Katholieke Universiteit Leuven, Leuven, Belgium
    Hum Mol Genet . 2016
    ..These findings reveal a new mechanism of NODAL signal transduction in the mammalian node and provide the first molecular explanation of how ZIC2 loss-of-function precipitates HPE...
  38. doi request reprint Expression of FOXP1 and Colorectal Cancer Prognosis
    Linde De Smedt
    Translational Cell and Tissue Research Unit, Department of Imaging and Pathologie, KU Leuven, Leuven, Belgium
    Lab Med 46:299-311. 2015
    ..Forkhead box gene P1 (FOXP1) has proven to be a valuable prognostic biomarker in lymphomas, but little is known about this gene in colorectal cancer (CRC)...
  39. pmc Single Nucleotide Polymorphism (rs4932178) in the P1 Promoter of FURIN Is Not Prognostic to Colon Cancer
    Jeroen Declercq
    Laboratory for Biochemical Neuroendocrinology, Department of Human Genetics, KU Leuven, 3000 Leuven, Belgium
    Biomed Res Int 2015:321276. 2015
    ..However, no association could be found. Altogether, we could not confirm an effect of the SNP on FURIN expression in vitro and no correlations could be found in vivo with FURIN expression or outcome. ..
  40. pmc The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling
    Layka Abbasi Asbagh
    Laboratory of Molecular Digestive Oncology, Department of Oncology, KU Leuven, Leuven, Belgium Laboratory for Mechanisms of Cell Transformation, VIB Center for the Biology of Disease, VIB, Belgium Center for Human Genetics, KU Leuven, Leuven, Belgium
    Oncotarget 5:10070-83. 2014
    ..Our results not only highlight the PTPRO contribution in negative regulation of SRC/EGFR signaling but also suggest that tumors with low PTPRO expression may be therapeutically targetable by anti-SRC therapies. ..
  41. ncbi request reprint Identification of IGFBP-6 as a significantly downregulated gene by beta-catenin in desmoid tumors
    Hannelore Denys
    Center for Human Genetics, University of Leuven, Leuven B 3000, Belgium
    Oncogene 23:654-64. 2004
    ..These findings suggest that IGFBP-6 is directly downregulated by the beta-catenin/TCF complex in desmoid tumors, and imply a role for the IGF axis in the proliferation of desmoid tumors...
  42. doi request reprint Feedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells
    Albert Bosch-Vilaró
    Laboratory of Molecular Digestive Oncology, Department of Oncology, KU Leuven, Leuven, Belgium
    Oncotarget . 2016
    ..Taken together, we provide evidence of the limited effectiveness of cetuximab monotherapy compared to rational combinations...
  43. doi request reprint Personalized medicine in metastatic colorectal cancer treated with anti-epidermal growth factor receptor agents: a future opportunity?
    Sabine Tejpar
    Digestive Oncology Unit, University Hospital Gasthiusberg, Leuven, Belgium
    Asia Pac J Clin Oncol 10:2-10. 2014
    ....
  44. doi request reprint The ZIC gene family encodes multi-functional proteins essential for patterning and morphogenesis
    Rob Houtmeyers
    Department of Oncology, Katholieke Universiteit Leuven, O and N1, 3000, Leuven, Belgium
    Cell Mol Life Sci 70:3791-811. 2013
    ..The identification of ZIC mutations in congenital syndromes highlights the relevance of these genes in human development...
  45. pmc Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer
    Erin M Coffee
    Division of Gastroenterology, Tufts Medical Center, Boston, Massachusetts 02111, USA
    Clin Cancer Res 19:2688-98. 2013
    ..Although selective BRAF inhibitors are effective for treatment of melanoma, comparable efforts in CRC have been disappointing. Here, we investigated potential mechanisms underlying this resistance to BRAF inhibitors in BRAF(V600E) CRC...
  46. ncbi request reprint Clinical validation of high-resolution fast spin-echo MR colonography after colon distention with air
    Didier J L E Bielen
    Department of Radiology, University Hospital Gasthuisberg K U Leuven, Leuven, Belgium
    J Magn Reson Imaging 22:400-5. 2005
    ..Before multishot 2D T1wFSE colonography can become a valid screening method, improved patient preparation and a more practical technique are needed...
  47. pmc Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia
    Wouter M Tiel Groenestege
    Department of Physiology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    J Clin Invest 117:2260-7. 2007
    ..Furthermore, we show that colorectal cancer patients treated with cetuximab, an antagonist of the EGFR, develop hypomagnesemia, emphasizing the significance of EGF in maintaining Mg(2+) balance...
  48. ncbi request reprint Assessment of endostatin gene therapy for familial adenomatous polyposis-related desmoid tumors
    Sandra C M Martinico
    Institute of Cancer and Cancer Research UK Clinical Centre, Barts and The London Queen Mary s School of Medicine and Dentistry, London, UK
    Cancer Res 66:8233-40. 2006
    ..Considering the current lack of effective treatment against desmoid tumors, we advocate that endostatin gene therapy represents an attractive new therapeutic approach for this disease...